DPYSL2 and urinary bladder cancer: Our own sequencing data found that the expression level of COMP/DPYSL2 in bladder cancer cases with response to tislelizumab combined with nab-paclitaxel therapy significantly decreased after treatment; however the expression level of TMPRSS4 increased after treatment in non-responsive cases (Figures 11C–H).